- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01580137
Acute Upper Respiratory Tract Infection - When is Bacteria Involved?
October 29, 2013 updated by: Oulu University Hospital
The purpose of this study is to find out if we can predict the progress of acute upper respiratory tract infection to acute bacterial rhinosinusitis in Finnish conscripts by symptoms, clinical, endoscopic or radiological findings, middle meatal swab samples or nitric oxide measurement.
Study Overview
Status
Unknown
Detailed Description
We will recruit conscripts with upper respiratory tract infection (common cold) during a two month period.
We will recruit non-allergic conscripts.
These conscripts should either have not had history of recurrent ABR or they should have experienced recurrent acute (ABR) bacterial rhinosinusitis at least 3 times during the last two years (diagnosed by a doctor and at least one time with x-ray or sinus puncture).
The recruits will keep a record of their symptoms.
They will be examined by a doctor soon after the symptoms have started (2-4 days) and when the symptoms have lasted about 7-10 days.
Clinical examination, nasal endoscopy and ultrasonographic examination of the maxillary sinuses are made, middle meatal specimen for bacteria and bacteria-pcr are taken, virus-pcr samples are taken from the nostril and nasopharynx, Nitric oxide-measurements from both nasal cavities are recorded.
Cone beam CT of the maxillary and ethmoidal sinuses is made during the first examination, 2-4 days later and during the last examination.
If the last CT-scan shows any other radiological signs than mild mucosal oedema in either maxillary sinus, maxillar sinus puncture is made and secretion is aspirated for culture and PCR.
Biopsy from the mucosa of nasal cavity (middle meatal area) is taken to examine the cilia and possible bacteria biofilm.
Study Type
Observational
Enrollment (Anticipated)
48
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kainuu
-
Kajaani, Kainuu, Finland, FI 87500
- Finnish Defence Force, Centre for Military Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 28 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Finnish conscripts from the prigade of Kainuu who suffer from acute common cold with nasal symptoms.
Consecutive sample.
Subjects with known allergies, nasal polyps and prior sinus surgery are excluded.
Description
Inclusion Criteria:
- Conscript with acute upper respiratory tract infection symptoms (nasal obstruction/decongestion, post nasal drip or nasal secretion) lasted for 2-4 days
Exclusion Criteria:
- Allergy, asthma, nasal polyposis, sinus surgery, autoimmune illness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
healthy conscripts
non allergic subjects who have not a history of recurrent rhinosinusitis
|
subjects with recurrent rhinosinusitis
subjects who have experienced recurrent rhinosinusitis episodes (3 during the previous 3 years)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bacterial maxillary sinusitis
Time Frame: 2 months
|
Bacterial maxillary sinusitis defined as positive culture results from the maxillary puncture (either side)
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bacterial sinusitis
Time Frame: 2 months
|
positive bacterial pcr results from either maxillary sinus
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Petri Koivunen, Dosent, Dept of Otolaryngology, University of Oulu, Finland
- Principal Investigator: Timo Koskenkorva, MD, Dept of Otolaryngology, University of Oulu, Finland
- Principal Investigator: Mervi Närkiö, MD, Finnish Defence Force
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (ACTUAL)
April 1, 2012
Study Completion (ANTICIPATED)
April 1, 2014
Study Registration Dates
First Submitted
April 17, 2012
First Submitted That Met QC Criteria
April 17, 2012
First Posted (ESTIMATE)
April 18, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
October 30, 2013
Last Update Submitted That Met QC Criteria
October 29, 2013
Last Verified
October 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Diary number 235/2011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Upper Respiratory Tract Infection and Acute Bacterial Rhinosinusitis
-
Zhong WangRecruitingBacterial Infection | Upper Respiratory Tract Infection | Chinese Medicine | Pediatric Acute Upper Respiratory Tract InfectionChina
-
Hanmi Pharmaceutical Company LimitedUnknownAcute Upper Respiratory Infection | Acute BronchitisKorea, Republic of
-
Daewon Pharmaceutical Co., Ltd.CompletedFever | Acute Upper Respiratory InfectionKorea, Republic of
-
Neutec Ar-Ge San ve Tic A.ŞRecruitingEfficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis.Sinusitis | Rhinosinusitis | Sinus Infection | Sinusitis, Acute | Rhinosinusitis AcuteTurkey
-
Altesa Biosciences, Inc.Virtus Respiratory ResearchRecruitingRCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory InfectionInfections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | Enterovirus Infections | Copd | Pulmonary Disease | Respiratory Disease | Respiratory Complication | Upper Respiratory Tract Infections | Respiratory Viral Infection | ... and other conditionsUnited Kingdom
-
China Academy of Chinese Medical SciencesGuangdong Provincial Hospital of Traditional Chinese Medicine; Guang'anmen... and other collaboratorsUnknownAcute Upper Respiratory InfectionChina
-
Guangzhou Yipinhong Pharmaceutical CO.,LTDCompletedAcute Upper Respiratory InfectionChina
-
Guangzhou Yipinhong Pharmaceutical CO.,LTDCompletedAcute Upper Respiratory InfectionChina
-
Washington University School of MedicineNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Boryung Pharmaceutical Co., LtdCompletedChronic Rhinosinusitis | Acute Rhinosinusitis | Recurrent Acute RhinosinusitisKorea, Republic of